CUSP9
 | This article, CUSP9, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
Comment: Some coverage in research articles, but I'm unsure if it's enough. FoCuSandLeArN (talk) 16:06, 12 June 2015 (UTC)
CUSP9 is one of several cancer treatment protocols using re-purposed older drugs to interfere with cancer cell's growth rather than directly killing them with cytotoxic drugs.[1][2] CUSP9 is a treatment of glioblastoma that uses growth factor inhibition by nine older non-cytotoxic drugs to block growth along with a traditional cancer cell killing drug, temozolomide. CUSP9 is related to the COMBAT regimen[3] for treating various advanced pediatric cancers that uses two re-purposed older non-cytotoxic drugs to augment two traditional cytotoxic drugs, or the GLAD[4] regimen that uses one traditional anti-cancer drug, gefitinib, with three re-purposed non-cancer drugs. The ReDO project[5] also follows this line of thought in cancer treatment.
None of these treatment regimens have been proven to be safe or effective in human cancers but are occasionally tried on compassionate-use basis in patients who have exhausted all other options. A formal trial of the CUSP9 protocol in recurrent glioblastoma is starting in Ulm, Germany.[6]
References
- ^ CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget. 2014;5(18):8052-82. PubMed PMID: 25211298.
- ^ A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget. 2013;4(4):502-30. PubMed PMID: 23594434; PubMed Central PMCID: PMC3720600.
- ^ Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience. Oncology. 2012;82(5):249-60. doi: 10.1159/000336483.
- ^ Multitargeted low-dose GLAD combination chemoprevention: a novel and promising approach to combat colon carcinogenesis. Neoplasia. 2013;15(5):481-90. PubMed PMID:23633920; PubMed Central PMCID: PMC3638351.
- ^ Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP, Vikas P. The Repurposing Drugs in Oncology (ReDO) Project. ecancermedicalscience. 2014;8:442. doi:10.3332/ecancer.2014.442.
- ^ "CUSP9*, 9 nine repurposed drugs, glioblastoma, temozolomide - Anticancer Fund". anticancerfund.org.